MicroPort MedBot Forecasts Revenue Surge and Sharply Narrowed Loss on Toumai Robot Boom

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) just unveiled an announcement.

Shanghai MicroPort MedBot expects its 2025 revenue to grow by about 110% to 120% year on year, driven primarily by breakthrough commercialization of its flagship Toumai laparoscopic surgical robot. Toumai has gained strong traction overseas, securing more than 100 new overseas orders in 2025 and boosting international sales revenue to over five times the previous year, bringing total global commercial orders above 180 and installed units beyond 120. The group also anticipates a substantial narrowing of its adjusted net loss to no more than RMB240 million, more than halving from 2024, helped by rapid revenue growth and cost-cutting and efficiency measures, while net free cash outflow is projected to shrink by over 80% to no more than RMB70 million, indicating improving operational efficiency and a strengthening financial profile for investors to watch as the business scales.

The most recent analyst rating on (HK:2252) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H

Shanghai MicroPort MedBot (Group) Co., Ltd. is a China-based medical robotics company focused on the research, development and commercialization of surgical robots. Its core product is the Toumai® Laparoscopic Surgical Robot, targeting both domestic and overseas hospitals and healthcare institutions as part of its strategy to expand in the global surgical robotics market.

Average Trading Volume: 4,513,774

Technical Sentiment Signal: Buy

Current Market Cap: HK$27.58B

For detailed information about 2252 stock, go to TipRanks’ Stock Analysis page.